Heart drug trial offers new hope for adults born with heart conditions
NCT ID NCT07354880
Summary
This study is testing if a medication called tirzepatide, which is approved for weight loss, can improve heart function and metabolic health in obese adults who were born with heart defects. About 30 participants will receive either the drug or a placebo for 24 weeks to see if it improves their exercise capacity, heart function, and cholesterol levels. The goal is to see if managing obesity can help control the long-term heart risks in this specific patient group.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.